The seismic impact of GLP-1s continues to be felt, with news that McDonald’s shares have dropped as weight-loss jabs transform our eating habits.
GLP-1 receptor agonists – the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) – have transformed the treatment of obesity and type 2 diabetes. But as their use has grown, so too have questions about a side effect that many patients notice but few feel prepared for: hair loss.
If you have started a weight loss injection and noticed more hair than usual in the shower or on your pillow, you are not alone. Here, we look at what the evidence tells us about what is often called Ozempic hair loss, why it happens, and what can be done.
Hair loss associated with GLP-1 medications has been reported since the landmark SURMOUNT-1 clinical trial for tirzepatide, in which 5.7% of participants experienced alopecia compared with 1% in the placebo group. Similar signals emerged from the STEP trials for semaglutide.
A 2025 letter published in the Journal of Cosmetic Dermatology highlighted a retrospective cohort study by Burke et al., which identified a notable association between GLP-1 receptor agonist use and an increased incidence of alopecia.
The authors called for prospective, randomised controlled studies to better define the strength of this relationship. The paper also highlighted data from the FDA Adverse Event Reporting System (FAERS), which showed a disproportionately higher reporting rate for hair loss among users of semaglutide compared with the general drug database, with a reporting odds ratio of 3.49, suggesting the association is unlikely to be coincidental.
Taken together, the evidence points to a real and clinically meaningful phenomenon, even if the mechanisms and precise incidence rates are still being characterised.
The speed of weight reduction matters as much as the amount. Sudden caloric restriction – even when medically supervised – is a recognised trigger for telogen effluvium. The body, under metabolic stress, deprioritises non-essential processes such as hair growth.
Reduced appetite on GLP-1 medications can lead to inadequate intake of protein and micronutrients essential to hair health – in particular, iron, zinc, biotin and B vitamins. Even subtle deficiencies can affect the hair cycle.
GLP-1 receptors are present in hair follicle tissue, raising the possibility that the medications may have a direct, though poorly understood, influence on follicle biology.
“It is also important to note that not all hair loss during GLP-1 treatment is caused by the medication itself. At Hardwick Clinic, we always consider and exclude other diagnoses, such as androgenetic alopecia, thyroid dysfunction, iron-deficiency anaemia, and scarring alopecia,” Tatyana warns.
“Scarring alopecia, in particular, should never be missed, as it can lead to permanent hair loss if left untreated.”
For most people, the answer is yes. Telogen effluvium is generally self-limiting. Once the precipitating stress resolves – whether that means the rate of weight loss slows, nutritional status improves, or the body adapts to the medication – hair typically begins to regrow within three to six months.
That said, ‘self-limiting’ does not mean ‘trivial’. For many patients, the psychological impact of hair shedding is significant, and reassurance alone may not feel sufficient, particularly when shedding continues for several months. Early assessment and, where appropriate, targeted treatment can make a meaningful difference.
At Hardwick Clinic, we take a structured approach to managing hair loss in patients on GLP-1 therapy. The guiding principle is to address the trigger first, then consider targeted treatment guided by the individual’s presentation and the degree of impact on their quality of life.
“The first step is a thorough assessment,” Tatyana explains. “We review nutritional status, blood markers, and the rate of weight loss. Where deficiencies are identified – iron, zinc, protein, vitamin B12 – these are corrected.”
We also consider the psychological dimension: chronic stress is itself a driver of telogen effluvium and should not be overlooked. Where the rate of weight loss appears to be a significant factor, this may be reviewed.
Where active treatment is warranted, options include topical and oral minoxidil (the latter used off-label), low-level laser light therapy (LLLT), and compounded formulations tailored to the patient’s hair-loss subtype. “Treatment is always guided by phenotype, which is the specific pattern and cause of hair loss,” explains Tatyana, “rather than applied uniformly.”
For patients with more pronounced or persistent hair loss, regenerative treatments offer additional benefit. Platelet-rich plasma (PRP) remains the best-supported regenerative option, with a growing body of clinical evidence for its role in stimulating follicle activity. Microneedling is a useful adjunct. “Emerging modalities – including polynucleotides, exosomes, stem cell secretomes, and mesotherapy – represent an exciting frontier, with promising early data that we continue to monitor closely.”
If you are experiencing hair loss while taking a GLP-1 medication, a formal assessment is always worthwhile – not only to understand whether the medication is the cause, but to exclude other diagnoses and ensure you are not missing something that requires more urgent attention.
Weight loss jabs can produce remarkable results for metabolic health, and hair shedding does not mean you need to stop treatment. With the right assessment and support, it is a side effect that is very often manageable.
Get in touch today to arrange a consultation.
Hardwick Clinic. 227 St. Neots road, Hardwick, Cambridge, CB23 7QJ
**Results and pictures are indicative only. Actual results may vary from patient to patient© 2026 Hardwick Clinic | Terms & Conditions | Website by the Web Marketing Clinic
